Biogen's leading tau-targeting candidate has slowed cognitive decline across a suite of different clinical assessments, ...
Candel has engaged Parexel International to support execution of this global pivotal trial NEEDHAM, Mass., June 30, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: ...
VIRAGE2 exploratory study designed to refine dosing regimen to potentially improved outcomes in a future pivotal Phase 3 clinical trial -- ...
SystImmune Inc. (SystImmune) today announced that its parent company, Sichuan Biokin Pharmaceutical Co., Ltd. (Biokin), has received regulatory approval from China's National Medical Products ...
NEEDHAM, Mass., June 30, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal ...
HIV treatment has progressed significantly since the 1980s. ART enables viral suppression and prevents transmission, but HIV ...
A new preclinical study from the University of Texas MD Anderson Cancer Center has identified a gut bacterium that, when ...
Designation supports development in an estimated $1 billion market where there are no FDA-approved therapies for patients whose disease ...
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that it has entered into a collaboration with Memorial Sloan Kettering Cancer Center (MSKCC) to advance a Phase II clinical study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results